

CRO Communiqué

Keeping you informed about CRO progress

May 2012

Top Enrolling Physicians for April 2012

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Bonebrake	2	2	0	2
Dr. Biggers	2	0	2	2
Dr. Bond	1	0	1	1
Dr. Carlson	1	1	0.5	1.5
Dr. Cunningham	1	1.5	0	1.5
Dr. Nevils	1	0	1	1
TOTALS	8	4.5	4.5	9

With one month left in our grant year, we have exceeded our NCI assigned cancer control credits of 60 by 11.9 having earned 71.9 credits. We have earned 100.3 treatment credits. We need to earn 19.7 additional treatment credits in May to meet our NCI assigned treatment credits of 120 for this grant year. All credits combined CRO has earned 172.2 credits. Combined NCI assigned us to earn 180 this grant year. We are very close and I know we will make our 180 credit assigned goal. Thanks to all our investigators and staff.

Steering Committee Meeting (Please note date changed to May 10, 2012)

Our next CRO Steering Committee will be Thursday, May 10th at TOUCH Restaurant. Alain Mita MD, Co-Director, Experimental Therapeutics Program at Cedar-Sinai Medical Center will speak on “The Molecular Basis of Lung Cancer: Expand your Understanding on Lung Cancer Biology”. Educational objectives for this program include:

- Refresh key concepts in cell-signaling pathways related to cancer biology
- Update knowledge on targeted therapeutic approaches and their mechanisms of action in an unbranded environment
- Share experiences and network with fellow oncologists through scientific discussions in a collegial atmosphere

The date for this event has been changed to accommodate the Mercy physician’s annual meeting. Please RSVP to Debbie.Cane@CoxHealth.com or 417-269-4520 by May 4, 2012.

CRO Web based monthly Educational Conference

Monday, May 7th at 12 noon will be the first WebEx conference to discuss new studies and other things happening in research at CRO. Tuesday, May 8th at 5pm the conference call will be repeated. CRO investigators, nurse practitioners and research staff will be sent an email inviting them to the conference. The invite will include a link to pull the conference up on their screen and a number to dial in. The conference will automatically be posted on the recipient’s calendar. Dr. Carolla will be presenting new studies available to our CCOP. Discussion and input from participants will be sought. The calls will include educational updates also. We will be hosting two calls per month initially to meet the preferences of the medical oncologists at Cox and Mercy. Conference calls will be scheduled monthly on the Monday before the second Tuesday of the month at 12noon and the second Tuesday of the month at 5pm. CRO staff will be setting up the conference rooms at Cancer Hematology Center and Oncology Hematology Associates for our investigators and interested staff to join in as a group. If this is helpful and well attended we will make further plans to do this on a permanent basis. The WebEx tool is highly interactive with logon capabilities from home computers, iPhones, iPads, Blackberries and so on as well as video capabilities with a web-cam. Please email Debbie Cane at Debbie.Cane@CoxHealth.com or myself at Marilyn.Bauer@CoxHealth.com with your contact information if you wish to receive notice of our monthly conferences and are not an investigator, nurse practitioner or member of our staff in Springfield. We see this as an opportunity to improve communications with our investigators and research staff. CME’s will be given for attendance.

Restructuring of CCOP’s

NCI announced it is combining its community-based research networks to create a single network that builds on their strengths. The Community Clinical Oncology Program Network, including Community Clinical Oncology Programs (CCOPs), Minority-based Community Clinical Oncology Programs (MB-CCOPs), Research Bases, and the NCI Community Cancer Centers Program (NCCCP) will be united to create the NCI Community Oncology Research Program or N-CORP. We will keep you updated as we hear more from NCI on this major restructuring.

CRO Affiliate Visits

Dr. Carolla, Marilyn Bauer, Basava Raju and Debbie Cane traveled to Rolla for a tour and visit with our Phelps County affiliate on April 24th. We will be traveling to Joplin for an internal audit and visit with Freeman investigators and staff on Thursday, May 24th.

New Studies Approved in April 2012

Opened at Cox and Mercy Springfield

SWOG S1117 A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs Azacitidine Alone vs Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

SWOG S1201 A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer

Opened at Mercy Springfield only

CTSU NCCTG N1048 A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Studies Permanently Closed to Enrollment at Cox & St. John's in April 2012

CALGB 80405 A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab Adenocarcinoma of the Colon or Rectum for Patients with Untreated Metastatic

NCCTG N0937 Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer

RTOG 0831 A Randomized, Double-Blinded, Placebo-Controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated with Radiotherapy for Prostate Cancer [Prevention of Erectile Dysfunction Study (PEDS)]

SWOG 0500 Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment

SWOG S0802 A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)